Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Meenakshi Hariharan"'
Autor:
Balaji Veeraraghavan, Yamuna Devi Bakthavatchalam, Abi Manesh, Binesh Lal, Subramanian Swaminathan, Abdul Ansari, K. Subbareddy, Pradeep Rangappa, Anirban Hom Choudhuri, Vasant Nagvekar, Yatin Mehta, Boppe Appalaraju, Sujata Baveja, Shrikala Baliga, Suchitra Shenoy, Renu Bhardwaj, Vaishali Kongre, Gogi Suresh Dattatraya, Binita Verma, D.N. Mukherjee, Shalini Gupta, Priyadarshini Shanmugam, Jyoti Iravane, Sudhi Ranjan Mishra, Purabi Barman, Shimpi Chopra, Meenakshi Hariharan, Rajendra Surpam, Rana Pratap, Dilip Turbadkar, Shripad Taklikar
Publikováno v:
Indian Journal of Medical Microbiology. 41:71-80
Levonadifloxacin (intravenous) and alalevonadifloxacin (oral prodrug) are novel antibiotics based on benzoquinolizine subclass of fluoroquinolone, licensed for clinical use in India in 2019. The active moiety, levonadifloxacin, is a broad-spectrum an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9fff65bb7b9cf551dca79aaa450345c
https://doi.org/10.1016/j.ijmmb.2022.11.005
https://doi.org/10.1016/j.ijmmb.2022.11.005
Autor:
Sudhi Ranjan Mishra, Debaprasad Mukherjee, Suchitra M Shenoy, Tapan N. Dhole, Priyadarshini Shanmugam, Rajendra Surpam, Gogi Suresh Dattatraya, Binita Verma, Rana Pratap, Shalini Gupta, Jyoti A. Iravane, Sachin Bhagwat, Sujata Baveja, Meenakshi Hariharan, B Appalaraju, Purabi Barman, Rishi Jain, Ashish Mane, Hemant Khande, Shrikala Baliga, Prashant Joshi, Shimpi Chopra, Vaishali Kongre, Renu Bhardwaj
Publikováno v:
The Journal of antimicrobial chemotherapy. 75(3)
Background Levonadifloxacin is a novel antibiotic belonging to the benzoquinolizine subclass of fluoroquinolones with potent activity against MRSA and quinolone-resistant Staphylococcus aureus. IV levonadifloxacin and its oral prodrug alalevonadiflox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9edc6efc1ce5ee4d50cb97292cdd5f9a
https://pubmed.ncbi.nlm.nih.gov/31840170
https://pubmed.ncbi.nlm.nih.gov/31840170